BNMS Oncology and Theranostics Symposium

The BNMS Oncology & Theranostics Symposium represents the cutting edge of modern medicine: the integration of diagnostics and therapeutics into a single, cohesive patient journey. This two-day conference in Nottingham focuses on the "See it, Treat it" philosophy that is revolutionizing the management of prostate cancer and neuroendocrine tumors. As theranostic centers expand across the UK, this event provides the necessary framework for clinicians to establish and scale their own programs.

The symposium kicks off with a series of keynote addresses from international pioneers in Lutetium-177 PSMA therapy. These sessions cover patient selection criteria, dosimetry calculations, and the management of side effects. A significant portion of the first day is dedicated to the infrastructure requirements of a theranostics suite, including radiation protection for therapy rooms and the specialized nursing care required for patients undergoing radionuclide therapy.

On day two, the focus shifts to the future of oncology. This includes the exploration of "The Next Wave" of theranostic pairs, such as Terbium isotopes and FAP-targeted ligands. There is also a dedicated session on the role of Artificial Intelligence in predictive dosimetry, showcasing how AI can help tailor the administered dose to the individual's unique tumor biology. The event concludes with a multidisciplinary panel involving oncologists, surgeons, and nuclear medicine physicians, emphasizing the importance of the "Theranostics Board" in decision-making. This symposium is essential for any professional looking to be at the forefront of the precision medicine revolution in the UK.